Market Cap 5.27B
Revenue (ttm) 3.55M
Net Income (ttm) -599.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -16,887.04%
Debt to Equity Ratio 0.46
Volume 3,506,600
Avg Vol 2,043,548
Day's Range N/A - N/A
Shares Out 138.26M
Stochastic %K 52%
Beta 1.27
Analysts Strong Sell
Price Target $46.38

Company Profile

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitryp...

Industry: Biotechnology
Sector: Healthcare
Phone: 626 304 3400
Fax: 626 304 3401
Address:
177 East Colorado Boulevard, Suite 700, Pasadena, United States
Steppinstone
Steppinstone Nov. 22 at 2:33 PM
$ARWR If Fazirsiran Phase 3 guidance is accurate then that means ARWR will launch Redemplo for FCS 2025/2026, Redemplo SHTG 2026/2027, Zodasiran for HoFH 2027/ 2028 and Fazirsiran 2028/2029. That is incredible commercial growth for a biotech.
0 · Reply
CarolyndrAckerson
CarolyndrAckerson Nov. 22 at 2:23 PM
#UFG Announces Zacks Small Cap Research Report with a Target Price of $7 a share. Watch live here: https://youtu.be/WGG9sDmnkck?si=ftUGMS-qViwx6CAs $ARWR $YOU $HTCO $MFI $CTRA
0 · Reply
Steppinstone
Steppinstone Nov. 22 at 2:05 PM
$ARWR Fazirsiran is guided to be fully enrolled by Feb. 2026 or in 3 months according to clinical trials info. This is a huge first to market A1AT drug where ARWR splits profits 50/50 in US with TAK. Plus a milestone payment should be triggered.
0 · Reply
Kgoose
Kgoose Nov. 22 at 1:34 PM
$ARWR once Wallstreet figures out that this Redemplo pricing strategy is to dominate the market, setting us up for sHTG domination, we will begin our march to triple digits imo. 2026 is going to be a great year, lots of data and suspect another partnership or two and some actual revenue generated not from partnerships or milestones and finally putting to use our beautiful mfg plant. Redemplo, better drug, better patient compliance, better pricing and self-administered, patients will want this!
0 · Reply
Kgoose
Kgoose Nov. 22 at 1:27 PM
$ARWR these large trades AH are head scratchers, equal to the daily volume block trade.
0 · Reply
fatchoy
fatchoy Nov. 22 at 12:11 PM
$ARWR https://clinicaltrials.gov/study/NCT07241546
1 · Reply
PrivateProfiteering
PrivateProfiteering Nov. 22 at 3:21 AM
$ARWR is currently trading at $40.45, with an RSI of 52.95, indicating neutral momentum. The 30-day moving average (MA30) is at $39.32, suggesting a bullish trend as the price is above this level. The 50-day moving average (MA50) at $36.95 further supports this bullish stance, as the price is significantly above it. The 60-day high of $43.69 provides a potential resistance level, while the low of $21.61 indicates a strong support base. Given the current metrics, the directional bias is bullish. Suggested entry is at $40.50, slightly above the last close to confirm upward momentum. Set a stop loss at $38.00 to manage risk. Target 1 is $43.00, near the 60D high, and Target 2 is $44.00, allowing for potential breakout gains. This plan capitalizes on the current bullish trend while managing risk effectively. For further insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 21 at 11:11 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ARWR $40.00 Put · DEC 19, 2025 Exp Entry Price: $4.60 - $6.00 Exit Price Target: $8.10 Profit Margin: +76% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Iightning
Iightning Nov. 21 at 10:19 PM
1ightning® Options Trade Alert (Actionable) | Buy $ARWR Dec 19 $45 Call | Enter: $2.52 Exit: $3.60 | Profit: 42.72% ROI | https://1ightning.com
0 · Reply
Pantherfan7979
Pantherfan7979 Nov. 21 at 9:54 PM
1 · Reply
Latest News on ARWR
US FDA approves Arrowhead's genetic disorder drug

Nov 18, 2025, 11:21 AM EST - 3 days ago

US FDA approves Arrowhead's genetic disorder drug


Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses'

Jun 4, 2025, 8:02 AM EDT - 6 months ago

Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses'


Arrowhead Pharmaceuticals Is Finally Arriving

Mar 21, 2025, 5:56 PM EDT - 8 months ago

Arrowhead Pharmaceuticals Is Finally Arriving


Steppinstone
Steppinstone Nov. 22 at 2:33 PM
$ARWR If Fazirsiran Phase 3 guidance is accurate then that means ARWR will launch Redemplo for FCS 2025/2026, Redemplo SHTG 2026/2027, Zodasiran for HoFH 2027/ 2028 and Fazirsiran 2028/2029. That is incredible commercial growth for a biotech.
0 · Reply
CarolyndrAckerson
CarolyndrAckerson Nov. 22 at 2:23 PM
#UFG Announces Zacks Small Cap Research Report with a Target Price of $7 a share. Watch live here: https://youtu.be/WGG9sDmnkck?si=ftUGMS-qViwx6CAs $ARWR $YOU $HTCO $MFI $CTRA
0 · Reply
Steppinstone
Steppinstone Nov. 22 at 2:05 PM
$ARWR Fazirsiran is guided to be fully enrolled by Feb. 2026 or in 3 months according to clinical trials info. This is a huge first to market A1AT drug where ARWR splits profits 50/50 in US with TAK. Plus a milestone payment should be triggered.
0 · Reply
Kgoose
Kgoose Nov. 22 at 1:34 PM
$ARWR once Wallstreet figures out that this Redemplo pricing strategy is to dominate the market, setting us up for sHTG domination, we will begin our march to triple digits imo. 2026 is going to be a great year, lots of data and suspect another partnership or two and some actual revenue generated not from partnerships or milestones and finally putting to use our beautiful mfg plant. Redemplo, better drug, better patient compliance, better pricing and self-administered, patients will want this!
0 · Reply
Kgoose
Kgoose Nov. 22 at 1:27 PM
$ARWR these large trades AH are head scratchers, equal to the daily volume block trade.
0 · Reply
fatchoy
fatchoy Nov. 22 at 12:11 PM
$ARWR https://clinicaltrials.gov/study/NCT07241546
1 · Reply
PrivateProfiteering
PrivateProfiteering Nov. 22 at 3:21 AM
$ARWR is currently trading at $40.45, with an RSI of 52.95, indicating neutral momentum. The 30-day moving average (MA30) is at $39.32, suggesting a bullish trend as the price is above this level. The 50-day moving average (MA50) at $36.95 further supports this bullish stance, as the price is significantly above it. The 60-day high of $43.69 provides a potential resistance level, while the low of $21.61 indicates a strong support base. Given the current metrics, the directional bias is bullish. Suggested entry is at $40.50, slightly above the last close to confirm upward momentum. Set a stop loss at $38.00 to manage risk. Target 1 is $43.00, near the 60D high, and Target 2 is $44.00, allowing for potential breakout gains. This plan capitalizes on the current bullish trend while managing risk effectively. For further insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 21 at 11:11 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ARWR $40.00 Put · DEC 19, 2025 Exp Entry Price: $4.60 - $6.00 Exit Price Target: $8.10 Profit Margin: +76% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Iightning
Iightning Nov. 21 at 10:19 PM
1ightning® Options Trade Alert (Actionable) | Buy $ARWR Dec 19 $45 Call | Enter: $2.52 Exit: $3.60 | Profit: 42.72% ROI | https://1ightning.com
0 · Reply
Pantherfan7979
Pantherfan7979 Nov. 21 at 9:54 PM
1 · Reply
AbovetheGreenLine
AbovetheGreenLine Nov. 21 at 8:38 PM
Swing Trade Buy on the Close for Arrowhead Pharma $ARWR, but it is already up 5 %. https://abovethegreenline.com/wp-content/uploads/2021/01
0 · Reply
johnnygogogo
johnnygogogo Nov. 21 at 7:10 PM
$ALNY the Palantir of bios / pharma. That sucking sound you hear today isn’t champagne slurps but rather the index factors changing on a Friday, exactly one month out from quarterly rebalance, quietly and begrudgingly recognizing that Alnylam isn’t a monopoly on commercial standalone RNAi companies anymore. Welcome to the party $ARWR @skeezbag @BikeRieder @LeftyT @Pantherfan7979 @simonsp
3 · Reply
skeezbag
skeezbag Nov. 21 at 3:36 PM
$ARWR for the dumb fuck bill. Gemini wrote it in sheep rather than goat for you
1 · Reply
Steppinstone
Steppinstone Nov. 21 at 3:17 PM
$ARWR Eli Lilly’s MC breaks 1 trillion. Obesity drugs obviously are doing well. Maybe ALK 7 for ARWR targeting adipose tissue can be a supplemental drug with the GLP1’s.
0 · Reply
LeftyT
LeftyT Nov. 21 at 1:00 PM
$ARWR I wonder if the 3 Amigos are using a DCF evaluation approach, or simply pulling numbers out of their sombreros that meet their greed meter guideline. It's nice to see some analysts, in this case Simply Wall St, actually use standardized DCF approach and list their assumptions! If you get a current intrinsic value of $58 using standard methods, how to the 3 Amigos get their future price target values???
1 · Reply
PrivateProfiteering
PrivateProfiteering Nov. 21 at 3:48 AM
$ARWR is currently trading at $38.09, which is below both the 30-day moving average (MA30) of $39.15 and the 50-day moving average (MA50) of $36.73, indicating a bearish trend. The RSI at 35.31 suggests the stock is approaching oversold conditions, which could lead to a potential reversal. However, the stock remains significantly above its 60-day low of $21.61, indicating that there is still room for downward movement. Given the current market context, a cautious approach is warranted. Suggested entry could be around $37.50, just above the MA50. A stop-loss should be placed at $35.50 to limit potential losses. For targets, consider $40.00, aligning with the MA30, and $42.00, near the 60-day high of $43.69, if momentum shifts positively. Monitor the ATR of 2.5 to gauge volatility and adjust stop-loss accordingly. https://privateprofiteers.com
1 · Reply
Iightning
Iightning Nov. 21 at 1:33 AM
1ightning® Options Trade Alert (Actionable) | Buy $ARWR Dec 19 $45 Call | Enter: $2.52 Exit: $3.60 | Profit: 42.72% ROI | https://1ightning.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 20 at 11:23 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ARWR $38.00 Put · DEC 19, 2025 Exp Entry Price: $3.20 - $3.50 Exit Price Target: $4.96 Profit Margin: +55% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
skeezbag
skeezbag Nov. 20 at 9:41 PM
$ARWR 1604 is back with a new code.....today markets the fourth day when there has been exactly 9 one share trades at 1604. The previous were 3 were sizable down days. 4, 6, or 8 one share trades at 1604 have previously been kind to the share price
1 · Reply
StockingStuffer2832
StockingStuffer2832 Nov. 20 at 9:31 PM
$ARWR holy smokes have you seen the December call volumes today?
0 · Reply
johnnygogogo
johnnygogogo Nov. 20 at 9:29 PM
$ARWR is JPM allowing buys yet? @simonsp
1 · Reply
TheSteveSmiths1
TheSteveSmiths1 Nov. 20 at 9:19 PM
$ARWR volume today was 3.6 million. twice the average, yet we held in a tight range most of the day. i wish i knew enough about market dynamics to have any clue what is going on “under the hood”
0 · Reply